M&A · Healthcare · Pharmaceutical Preparations
Insud Pharma, S.L. to acquire Agile Therapeutics Inc
Announced Jun 26, 2024 · Closed Aug 26, 2024
Deal value$45MEV $45M
Premium—To unaffected price
EV / Adj. EBITDA—2.1x EV / Revenue
ConsiderationAll cash$1.52 per share
Transaction
- Acquirer
- Insud Pharma, S.L.
- Target
- Agile Therapeutics Inc (AGRX)
- Buyer type
- Strategic
- Offer price per share
- $1.52
- Enterprise value
- $45M
- Status
- Closed Aug 26, 2024
Deal protections
- Break fee (target pays)
- $1.3M · 2.8%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- H.C. Wainwright
Sector context · Healthcare
- Comparable deals
- 109 in the prior 24 months
- Premium
- Sector median 63.5%
- EV / Adj. EBITDA
- Sector median 17.2x
- Break fee
- 2.8% vs. 3.5% sector median
Timeline
- AnnouncedJun 26, 2024
- Proxy filedJul 12, 2024
- Definitive proxyJul 25, 2024
- Shareholder voteAug 22, 2024
- ClosedAug 26, 2024
Valuation · fairness opinions
Precedent transactions$6.01$11.97
Offer $1.52
Implied value per Agile Therapeutics Inc share by analysis, from H.C. Wainwright · DCF discount rate 14.3%–19.3%.